Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187


Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.

Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ, Kim TY.

Oncogene. 2014 Jun 19;33(25):3334-41. doi: 10.1038/onc.2013.285. Epub 2013 Jul 22.


MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.

Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR.

Mol Cancer Ther. 2012 Mar;11(3):660-9. doi: 10.1158/1535-7163.MCT-11-0754. Epub 2012 Jan 11.


An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.


Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.

Zhang Z, Wang J, Ji D, Wang C, Liu R, Wu Z, Liu L, Zhu D, Chang J, Geng R, Xiong L, Fang Q, Li J.

Clin Cancer Res. 2014 Sep 1;20(17):4559-73. doi: 10.1158/1078-0432.CCR-13-3396. Epub 2014 Jun 27.


Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.

Lee YY, Kim HP, Kang MJ, Cho BK, Han SW, Kim TY, Yi EC.

Exp Mol Med. 2013 Nov 22;45:e64. doi: 10.1038/emm.2013.115.


Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.

Sato Y, Yashiro M, Takakura N.

Cancer Sci. 2013 Dec;104(12):1618-25. doi: 10.1111/cas.12290. Epub 2013 Oct 28.


Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.

Nam HJ, Ching KA, Kan J, Kim HP, Han SW, Im SA, Kim TY, Christensen JG, Oh DY, Bang YJ.

Mol Cancer Ther. 2012 Feb;11(2):439-51. doi: 10.1158/1535-7163.MCT-11-0494. Epub 2011 Dec 1.


Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.

Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.

Clin Cancer Res. 2010 Mar 1;16(5):1509-19. doi: 10.1158/1078-0432.CCR-09-1112. Epub 2010 Feb 23.


Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.

Mol Cancer Ther. 2010 Jun;9(6):1489-502. doi: 10.1158/1535-7163.MCT-09-1171. Epub 2010 May 25. Erratum in: Mol Cancer Ther. 2011 Nov;10(11):2211.


Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.

Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.

Mol Cancer Ther. 2012 Sep;11(9):1978-87. doi: 10.1158/1535-7163.MCT-11-0730. Epub 2012 Jul 3.


Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.

Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.

PLoS One. 2010 Feb 2;5(2):e9024. doi: 10.1371/journal.pone.0009024.


Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.

Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, Cui X, Murali R, Namba K, Sato H, Torigoe H, Watanabe M, Shien K, Soh J, Asano H, Tsukuda K, Kitamura Y, Miyoshi S, Sendo T, Toyooka S.

PLoS One. 2017 Feb 3;12(2):e0171356. doi: 10.1371/journal.pone.0171356. eCollection 2017. Erratum in: PLoS One. 2017 Mar 16;12 (3):e0174493.


Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.

Oshima Y, Tanaka H, Murakami H, Ito Y, Furuya T, Kondo E, Kodera Y, Nakanishi H.

Gastric Cancer. 2014;17(3):450-62. doi: 10.1007/s10120-013-0290-6. Epub 2013 Aug 15.


Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.

Shibata T, Kan H, Murakami Y, Ureshino H, Watari K, Kawahara A, Kage M, Hattori S, Ono M, Kuwano M.

Mol Cancer Ther. 2013 May;12(5):737-46. doi: 10.1158/1535-7163.MCT-12-1125. Epub 2013 Feb 27.


Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.

Huang D, Duan H, Huang H, Tong X, Han Y, Ru G, Qu L, Shou C, Zhao Z.

Sci Rep. 2016 Feb 5;6:20502. doi: 10.1038/srep20502.


Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR.

Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23.


Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.

Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Mochizuki Y, Koike M, Fujiwara M, Nakao A, Tatematsu M, Nakanishi H.

Br J Cancer. 2006 Dec 4;95(11):1504-13. Epub 2006 Nov 7.


Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.

Liu L, Shi H, Liu Y, Anderson A, Peterson J, Greger J, Martin AM, Gilmer TM.

Mol Cancer Ther. 2011 Mar;10(3):518-30. doi: 10.1158/1535-7163.MCT-10-0698. Epub 2011 Jan 20.


Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.

Liu J, Chen X, Ward T, Mao Y, Bockhorn J, Liu X, Wang G, Pegram M, Shen K.

Int J Biochem Cell Biol. 2016 Feb;71:12-23. doi: 10.1016/j.biocel.2015.11.014. Epub 2015 Nov 28.


Supplemental Content

Support Center